5363592
Last Update Posted: 2023-01-12
Recruiting has ended
All Genders accepted | 19 Years-50 Years |
48 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase 1, single-center study to evaluate bioequivalence after co-administration of ALO and MET XR or administration of CT-L01 in healthy volunteers.
Eligibility
Relevant conditions:
Healthy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov